Coghlan, JG;
Picken, C;
Clapp, LH;
(2019)
Selexipag in the management of pulmonary arterial hypertension: an update.
Drug, Healthcare and Patient Safety
, 11
pp. 55-64.
10.2147/DHPS.S181313.
Preview |
Text
Selexipag in the management of pulmonary arterial hypertension an update.pdf - Published Version Download (320kB) | Preview |
Abstract
Selexipag is a compound that was designed to overcome the issues associated with oral administration of prostanoid compounds, beraprost and treprostinil in the treatment of pulmonary hypertension (PAH). As a selective IP agonist, it was designed to avoid the off-target prostanoid effects especially in the gastrointestinal system. To place this compound in context, this paper briefly reviews the efficacy, tolerability, and safety of subcutaneous, inhaled, and oral prostanoid preparations and comparesthemto selexipag. Selexipag is the first agent targeting a prostanoid receptor where a reduction in the primary efficacy morbidity/mortality composite end-point has been demonstrated. While safety outcomes favor selexipag over placebo, tolerability issues remain. Efficacy in terms of improvement in effort tolerance, hemodynamic and mortality benefit is less than seen with IV therapy. This is the first prostanoid demonstrated in a clinical trial to have added benefit in those on background double combination therapy and the first non IV prostanoid to demonstrate outcome benefit in the connective tissue disease (CTD) population in a randomized controlled trial.
Type: | Article |
---|---|
Title: | Selexipag in the management of pulmonary arterial hypertension: an update |
Location: | New Zealand |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.2147/DHPS.S181313 |
Publisher version: | https://doi.org/10.2147/DHPS.S181313 |
Language: | English |
Additional information: | © 2019 Coghlan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). |
Keywords: | prostacyclin, prostaglandin, safety, tolerability, adverse events, efficacy |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Pre-clinical and Fundamental Science |
URI: | https://discovery.ucl.ac.uk/id/eprint/10082805 |
Archive Staff Only
View Item |